Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

Two novel sub-types of multiple sclerosis (MS) have been identified, a discovery potentially paving the way for new treatments. Researchers employed artificial intelligence (AI) to assess brain scans ...

Thomas Leist, MD and Darin Okuda, MD provide insight into first-line treatment selection for MS and the patient factors involved. Maria Lopes, MD, MS discusses payer considerations and challenges in ...

OMAHA, Neb. (WOWT/Gray News) - A Nebraska woman has become the first patient in the world to undergo a groundbreaking new treatment for multiple sclerosis. Seven years ago, Jan Janisch-Hanzlik began ...

As the multiple sclerosis (MS) population ages, managing the condition can bring new challenges. For one woman, working closely with her doctor, exploring treatment options, and finding the right ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...